UNSPSC 51411500: Vasodilator carboxylic acids

Vasodilator drugs made from organic compounds containing the carboxy group (-COOH).

UNSPSC 51411500 Vasodilator carboxylic acids is a Class code covering pharmaceutical products used in emergency medical response and acute care settings—specifically advanced life support medications such as labetalol, diltiazem, adenosine, and epinephrine that state and local health systems procure for emergency departments, fire rescue operations, and pharmacy benefit programs. State and local buyers under this code include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. Work currently solicited ranges from direct supply contracts for emergency medications to strategic procurement initiatives exploring direct-to-manufacturer relationships and multistate generic pharmaceutical frameworks. The Tampa Fire Rescue solicitation exemplifies the emergency-response end of the market, while the Texas HHS and Minnesota MMCAP opportunities reflect broader pharmacy benefit program consolidation and cost management strategies that encompass vasodilators alongside other medication classes.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Bid No. 26P00188) on April 24, 2026, with a response deadline of April 8, 2026, for advanced life support medications including labetalol and diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus renewal options; the solicitation included a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs as part of a Therapeutic Pharmacy Initiative. The Minnesota Department of Administration, administering the MMCAP cooperative purchasing vehicle, issued an RFP (S1070000015802) with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. The MMCAP procurement emphasizes price competitiveness (75 percent evaluation weight), FDA compliance, cGMP and DSCSA certification, and relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson).